1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
P2Y12 receptor inhibitors in patients with non-STelevation acute coronary syndrome in the real world : Use, patient selection, and outcomes from contemporary European registries
(
- Contribution to journal › Article
-
Mark
Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries
(
- Contribution to journal › Article
- 2015
-
Mark
Improving outcomes in patients with coronary heart disease using national registers and platelet function testing
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Rational mutagenesis of pig liver esterase (PLE-1) to resolve racemic clopidogrel
(
- Contribution to journal › Article
-
Mark
Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI : an observational comparative study
(
- Contribution to journal › Article
- 2014
-
Mark
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease
(
- Contribution to journal › Article
- 2012
-
Mark
Hydrolases as Catalysts for Green Chemistry and Industrial Applications - Esterase, Lipase and Phytase
2012)(
- Thesis › Doctoral thesis (compilation)
- 2010
-
Mark
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
(
- Contribution to journal › Article
- 2009
-
Mark
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article
- 2008
-
Mark
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article